ONL Therapeutics Receives Phase II SBIR Grant From National Eye Institute for Development of Novel Retinal Disease Treatment
November 12, 2014 08:16 ET
|
ONL Therapeutics
ANN ARBOR, MI--(Marketwired - Nov 12, 2014) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced...